| Code | 64307 | ||||||||||
| MA number | EU/1/08/479/002 | ||||||||||
| Product Form: | plu igf 1x300 mg (liek.inj.skl.) +1x3 ml solv.(liek.inj.skl.) | ||||||||||
| MA Status: | E - Valid centralised marketing authorisation | ||||||||||
| Type of procedure: | EU | ||||||||||
| MAH, country: | CHEPLAPHARM Registration GmbH, Germany | ||||||||||
| Therapeutic Class: | 68 - ANTIPSYCHOTICA (NEUROLEPTICA) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intramuscular use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 8(3) application |
| MA issued: | 19.11.2008 |
| SmPC + PL: |
European Medicines Agency's database
|
| Dokument: |
ZypAdhera_Tréning prípravy lieku pre zdravotníckych pracovníkov.pdf
|
| Dokument: |
ZypAdhera_Edukačný program pre zdravotníckych pracovníkov.pdf
|
| Dokument: |
Zypadhera_Karta_pacienta.pdf
|
| Dokument: |
DHPC_Zypadhera_22.08.2025.pdf
|
| Safety feature | Yes |
| Data update: | 20.06.2018 |
